Background: Lung cancer is among the most common cancers. Search is ongoing to find biomarkers to improve the diagnosis lung cancer techniques in early stages. In this study we evaluate the sensitivity and specificity of the MUC1 and CEA gene expressions in the peripheral blood of non-small cell lung cancer (NSCLC). Material and Methods: This study was done in Masih Daneshvari Hospital, Tehran, Iran and was case/control study that conducted on 30 NSCLC patients and 30 healthy controls. Peripheral blood was collected and total RNA was extracted then cDNA was synthesized. Sample was separately assessed by real time PCR. Results: The expression of CEA gen was positive in 24 patients indicating 80% sensitivity for this marker. The expression of CEA gen was positive in 9 controls out of 30 each. A statistically significant difference was detected between patients and healthy controls with regard to CEA mRNA expression (P < 0.001). The MUC1 gen expressed in 20 out of 30 patients, while it expressed in 3 controls. The difference in MUC1 mRNA expression was statistically significant between NSCLC patients and How to cite this paper:
Introduction
Lung cancer is among the most common cancers worldwide and over 80% of the lung cancer patients have an approximately 5-year survival rate after diagnosis [1] . Lung cancer is categorized into two types of NSCLC and small cell lung cancer (SCLC). NSCLC is an epithelial tumor with a high invasive clinical stage. It has high rate of metastasis in early stages [2] [3] . In the past couple of decades, there was less attention to the therapeutic approaches for lung cancer [2] . Incidence of lung cancer is variable in different races and ethnic groups and it is the first cause of morbidity and mortality in the United States [3] . The overall risk of developing lung cancer is 8% for men and 6% for women [3] .
The occurrence of lung cancer is the result of tumoral growth and uncontrolled proliferation of pulmonary cells. Exposure to environmental carcinogens such as cigarette smoke causes dysplastic changes in bronchial epithelial cells and leads to neoplastic changes and malignancy. Moreover, some genetic factors predispose patients to malignant phenotypes [4] . Tumoral biomarkers are protein or glycoprotein molecules produced in response to presence or progression of cancer, which are found in body fluids and cancerous tissue [4] [5] [6] . To date, no tumoral biomarker has been identified for efficient prediction of patient prognosis. However, some markers are useful for diagnosis or prediction of tumor, determining the presence of metastasis or for selection and timing of therapeutic regimens [7] . Using affordable and non-invasive tumor biomarkers ease the pathway to cancer diagnosis [8] [9] [10] [11] .
The CEA is a set of glycoproteins produced in the liver during fetal development and its production ceases before birth. This marker is used for assessment of many types of cancer such as lung and pancreatic cancer. The tumor growth factor beta (TGF-B) mediates cell adhesion to extra-cellular matrix and regulates the expression of CEA. The CEA factor increases in lung cancer. Therefore, the expression of CEA increases, leading to consequent metastasis of cancer cells [12] [13] [14] . Expression of CEA decreases after the treatment starts and it indicates a positive response to treatment and growth inhibition of tumoral cells [15] . In previous studies, the sensitivity of CEA biomarker in lung cancer was higher than in other malignancies [16] [17] .
The MUC1 is a mucin encoded by MUC1 gene in humans; it is a glycoprotein with extensive O-linked glycosylation of its extracellular domain [18] . Mucin lines the apical surface of the lungs, stomach, intestines, eyes and some other organs [19] In this study, we investigate the level of expression of CEA mRNA and MUC1
mRNA by real-time RT-PCR in the peripheral blood of patients with NSCLC.
Also, we assess the sensitivity and specificity of the afore-mentioned two biomarkers for early detection and diagnosis of NSCLC for prompt treatment before metastasis.
Materials and Methods

Study Groups
In this case/control study, was conducted on two groups; first, the NSCLC pa- Those with no history of chemotherapy or surgery were chosen and blood samples were drawn prior to initiation of treatment. Second, healthy control group that were selected among subjects presenting to the same hospital with normal bronchoscopic or pathologic findings. The control subjects were matched with the patients in terms of age and sex.
Sample Collection
The objectives of the study were thoroughly explained to both test and control subjects and written informed consent was obtained from them. Subjects were requested to fill out a questionnaire asking for their demographics and disease status. Next, 10 mL of peripheral blood was drawn. The first 2 mL was discarded due to the risk of contamination with epithelial cells; the remaining 8 mL was transferred to a Falcon tube containing ethylenediaminetetraacetic acid (EDTA)
anticoagulant and sent to a laboratory for RNA extraction.
Red Blood Cell Lysis
As stated earlier, 8 mL of blood was used for RNA extraction. To lyse the RBCs, 32 mL of the RBC lysis buffer (four times the blood sample volume) was added Open Journal of Clinical Diagnostics to 8 mL of blood and the mixture was incubated for 30 minutes; the solution was vortexed for several times during this time period. The solution-containing vial was then centrifuged at 4000 ×g for 20 minutes; the supernatant was discarded and 8 mL of the lysis solution was added to the sediment and centrifuged at 3000 ×g for 10 minutes. The supernatant was discarded and the sediment containing white blood cells and tumoral cells was used for RNA extraction.
RNA Extraction
RNeasy Midi Kit (Qiagen Cat No. 75144) was used for RNA extraction. The sediment obtained in the previous step was first lysed using RLT lysing solution present in the lysis kit. Next, 70% ethanol was added and the solution was poured on the extraction column and centrifuged at 3000 g for 5 minutes. In the next step, RW1 and PRE solutions present in the kit were added to the column, respectively and centrifuged to eliminate the DNA, proteins and other impurities. The pure RNA was then extracted from the column using 250 μL of RNAsefree water. The quality and quantity of the extracted RNA were controlled by NanoDrop®. Based on the concentration of extracted RNA and maximum capacity of cDNA synthesis, 15 μL of each RNA vial was immediately used for cDNA synthesis.
Reverse Transcription
For reverse transcription, 15 μL of RNA was reverse transcribed to cDNA using Viva 2-step RT-PCR kit (Cat No. RTPL12). This process was repeated three times and three vials of cDNA were synthesized. Final testing was performed on each vial of each sample. The purity and quantity of cDNA were measured by NanoDrop®. The quality of cDNA for real-time RT-PCR was confirmed by observation of 18SrRNA expression in each sample.
Primers
Specific primers for each marker were designed using AlleleID7 software and ordered for synthesis. The sequence of primers and their amount used in the final reaction of real-time RT-PCR are presented in Table 1 .
Real-Time qRT-PCR
To assess the presence of Muc1 mRNA and CEA mRNA, cDNA vials were tested by real-time RT-PCR using HotTaqEvaGreenqPCRMix kit. The real-time RT-PCR reaction components included (A) 2 μL of the template, (B) 4 μL of the Master mix, (C) Primer with optimal concentration found in set up tests, (D) Deionized distilled water to reach a final reaction volume of 20 μL. Positive and negative controls were also used simultaneously for quality control and detection of possible contamination.
Statistical Analysis
Sample size was calculated taking into account the ratio of positivity for the N. Bahrami et al. markers in the two groups based on primary estimates in similar previous studies [24] as well as using sample size estimation formula considering type one error of 5% and type two error of 20%. The data were analyzed using SPSS version 22.
The mean values were compared between the two groups of test and control using t-test. Gene expression ratios in the two groups were statistically analyzed and compared using Chi square test. Level of significance was set at P ≤ 0.05.
Results
A total of 30 NSCLC patients and 30 healthy controls were evaluated. Of 30 patients, 24 were males and 6 were females. No statistically significant difference was noted between males and females in this regard either (P = 0.475).
Comparison of the mean age showed difference between patients and controls is not statistically significant (Table 2) .
Expression of 18SrRNA Reference Gene
The threshold cycle (Ct) value of 18SrRNA reference gene determined by PCR was reported for each sample. The mean Ct value was 18.83 in the group of patients and 17.27 in the group of healthy individuals; comparison of the mean Ct values revealed no statistically significant difference between the two groups (P = 0.102) and indicated that the selection of this biomarker as the reference gene was appropriate.
Analysis of the Expression of MUC1 mRNA and CEA mRNA
In the group of patients, 24 out of 30 were positive for CEA mRNA expression.
Thus, the sensitivity of this biomarker was 80%. Of the healthy individuals, 9 out (Table 3) . 
Difference in Expression of Biomarkers between the Two Groups of Patients and Controls
To make a comparison between the two groups of patients and controls with regard to the expression of the two biomarkers, ΔΔCt method was applied. The
ΔΔCt was calculated to be −0.4 for the CEA mRNA. Next, the −ΔΔCt formula was used, which revealed that the number of primary transcripts of this biomarker in patients was averagely 1.32 times the rate in healthy controls.
Also, ΔΔCt was found to be −2.78 for MUC1 mRNA; the −ΔΔCt formula showed that the number of primary transcripts of this biomarker in patients was averagely 6.87 times the rate in healthy controls ( Figure 2 and Table 4) .
Comparison of the level of positivity for the CEA mRNA revealed a significant difference between patients and healthy controls (P < 0.001). Comparison of the level of positivity for the MUC1 mRNA revealed a significant difference between patients and healthy controls (P < 0.011) as well. Simultaneous assessment of both biomarkers revealed that in a minimum of 29 patents, expression of one of the two biomarkers was positive, which corresponds to 96.6% of the cases.
Discussion
In this study, we evaluated the expression of CEA mRNA and MUC1 mRNA in [29] . A number of nonsmall cell lung cancer patients who are recognized in primary stages of the disease and undergo surgery die due to tumor recurrence, which shows presence of undetectable metastasis at the time of surgery. These laboratory findings show that the currently used staging system does not have sufficient sensitivity for compartmentalization of cancer patients [30] [31] .
Among diagnostic procedures, non-invasive methods such as detection of tumoral biomarkers have been the topic of many investigations for early detection of cancers. Tumoral biomarkers are of several types but mRNA biomarkers are detectable even in very low amounts; they are valuable biomarkers detectable by real-time RT-PCR, with acceptable sensitivity and specificity. The process is via extraction of RNA from the sample, cDNA synthesis by reverse transcription and final conduction of real time RT-PCR [25] [28] [32] .
Similar studies have shown that increasing the number of samplings (repeated sampling in several sessions) significantly increases the sensitivity of mRNA biomarkers [29] [30] . This indicates that the odds of detecting markers are lower in a single sampling. Studies on peripheral blood mainly search for tumoral cells to find positive and negative cases by RNA extraction. Obviously, by repeating the sampling for several times the odds of finding tumoral cells increase. Based on this assumption and since repeated sampling from patients was not possible we repeated the test on samples instead of repeating sampling on patients. The tests were performed in triplicate to significantly increase the sensitivity of the markers. This technique has been used in similar previous studies on different types of cancers, and the obtained results have been in line with our findings [12] [25] [31] [33] .
In the current study, real time PCR was used for evaluation of MUC1mRNA and CEA mRNA and Showed that MUC1mRNA was a specific marker for detection of non-small cell lung cancer. Also, a significant difference was noted in the expression of CEA mRNA between the patients and controls. In a study Karimi et al. said that LUNX mRNA was particularly expressed in the peripheral blood of non-small cell lung cancer patients. In addition, the expression of CEA mRNA was significantly higher in patients than in healthy controls since 24 out of 30 patients were positive for CEA mRNA [25] . Similarly, the difference in this consideration between patients and controls was statistically significant in this study.
In a study evaluating of CK19 markers and CEA marker was measured by ELISA and real time PCR method and has shown that these markers in patients more than healthy controls [34] .
In a similar study on diagnosis of lymph node, micro-metastasis of NSCLC of 43 non-small cell lung cancer tumoral samples 74% were positive for the MUC1, CK19 and CK7 markers [35] . However, in the current study, this value was 96.6% for the MUC1 and CEA markers in the peripheral blood of non-small cell lung cancer patients. Open Journal of Clinical Diagnostics MUC1 mRNA is a cell surface glycoprotein expressed in some cancers with epithelial origin such as non-small cell lung cancer. It induces the expression of genes, which are associated with poor prognosis in NSCLC patients [36] . A previous study showed that the blood level of MUC1 mRNA decreased over the course of treatment but it remained positive in 45.5% of NSCLC patients at four weeks after treatment [37] . Expression of MUC1 mRNA in the peripheral blood samples taken before and during the course of treatment shows significant potential of this biomarker for prediction of prognosis of non-small cell lung cancer [37] .
CEA mRNA and MUC1 mRNA biomarkers can be used for diagnosis of lung cancer with adequately high sensitivity and specificity. However, future investigations with larger sample size are required to find more reliable results. Also, adding other markers is required to find efficient biomarkers enabling more accurate diagnoses.
Conclusion
